Board of Directors
BSc (Hons) Maths & Stats
Executive Director and CEO
BSc (Hons) 1st Class, MSc, PhD
Ralph, a founding Director of VHT, has been at the forefront of the digital breast imaging field for over 25 years. Initially a research scientist at the University of Oxford, Ralph’s innovative work in quantitative breast imaging technology led him to form first OXIVA Limited and then Mirada Solutions with Professor Sir John Michael Brady. Under Ralph’s leadership Mirada became the number-one provider of image registration and fusion tools before being acquired by CTI Molecular Imaging Inc. and later Siemens Medical Solutions USA, Inc.
Before founding VHT in 2009, Ralph consulted for many of the world’s top medical imaging companies, including R2, Siemens, Hologic and Dexela, as well as many leading breast screening programs. During this time, he continued his academic research as part of an international circle of collaborators.
Ralph is the author of numerous articles and, with Brady, the seminal book Mammographic Image Analysis. As CEO of VHT, Ralph is dedicated to providing the most accurate measurements possible of breast composition (“breast density”) in order to improve the health outcomes of women around the world. Based in Wellington, New Zealand, in 2015 he was named a Wellingtonian of the Year finalist.
Roger Allen AM
BA (Hons), FACS
Roger joined the Board in June 2010 and was Chairman from October 2015 to March 2019. Roger is a highly experienced entrepreneur and investor in early-stage growth companies in Australia and internationally. He built Computer Power Group (CPG) in the 1970s from a small start-up to a worldwide group of 3,000 people operating from 50 offices in 12 countries, listing on the ASX in 1987. In 1996 he co-founded Allen & Buckeridge, an early-stage venture capital fund with offices in Silicon Valley and Australia. He is dedicated to social entrepreneurship, especially to enterprises focused on indigenous economic development and digital health.
Roger has served on two Prime Ministers’ Science and Technology Councils and Advisory Boards, and was Deputy Chairman of Austrade from 1990 to 1997. Currently an adjunct professor in the Business School of the University of Technology Sydney, he has also lectured occasionally at the School of Entrepreneurship at INSEAD. Roger has been awarded the top two lifetime awards in the IT industry (CSIRO Tony Benson award and the Pearcey Medal for lifetime achievement) as well as an Order of Australia Honour for his services to the IT sector through leadership roles, venture capital investment and professional development, and in recognition of his support of the indigenous community and philanthropic interests. He is based in Sydney, Australia.
Roger is a member of the Audit and Risk Committee.
Non-Executive Director & Chief Medical Officer
BSc, MS, MD
Monica joined the VHT Board in 2018. She is an internationally recognised expert in breast cancer, especially breast density and breast cancer risk assessment.
Monica is a Doctor of Medicine and a prior BSc in nursing. She has had U.S. radiology training and an additional fellowship in women’s imaging. She has over 10 years of patient care experience and was the Chief of Breast Imaging at Santa Fe Imaging/Christus St Vincent Hospital in the southwestern U.S. from 2008 to 2016. She also served as the chairman for the Christus St Vincent Cancer Committee.
In 2015, she became a medical advisor for GE Healthcare and consultant for ProScan Imaging, as well as research advisor for World Care Clinical. By 2016, she was appointed Medical Director of Automated Breast Ultrasound Systems, GE Healthcare. Globally, she worked on early detection of breast cancer, breast cancer research, and international physician education for breast imaging technologies.
Monica relocated to New Zealand in 2017 and started as a consultant for VHT where she implements hands-on expertise in product development, research, and customer relations. She also evaluates patients as a lead radiologist at Hutt Valley District Health Board in Wellington.
Professor Sir Mike Brady
FREng, FMedSci, HonFIE
Mike, a founding director of VHT, is currently Professor of Oncological Imaging at the University of Oxford, having recently retired after 25 years as Professor of Information Engineering. He served for 20 years as a non-executive director and deputy chairman of the FTSE 250 company Oxford Instruments plc and for 10 years as a non-executive director of AEA Technology plc.
Mike is founding director of Perspectum Diagnostics, which performs liver image analysis by MRI, and Mirada Medical Limited, which develops medical image analysis software and is installed in almost 2000 hospitals worldwide; ScreenPoint, which develops machine learning methods for computer-aided diagnosis in mammography; Optellum, which develops software to classify lung nodules in CT; and Guidance Navigation Holdings, which develops systems to aid navigation of vessels near large structures.
Mike is the author of over 750 articles and 35 patents in computer vision, robotics, medical image analysis and artificial intelligence, and the author or editor of 10 reference books. He is based in Oxford, UK.
John joined the VHT board in early 2015 with more than 25 years of medical device experience as an executive and company director, John currently serves as the President and CEO of VytronUS, Inc., a venture-backed start-up using novel catheter-based ultrasound and robotics technology to treat atrial fibrillation, a cardiac arrhythmia.
Prior to VytronUS, John was the President and CEO of Endoscopic Technologies, Inc., a leader in minimally invasive and endoscopic treatment of atrial fibrillation. Since 2007, John has also served on the board of directors of several health technology start-up companies, including U-systems, Inc., which pioneered automated breast ultrasound imaging as an adjunct to mammography for breast cancer screening and was acquired by GE Healthcare in 2012.
Previously, John served as President and CEO of R2 Technology Inc., the pioneer and leader in computer-aided detection of breast cancer, until Hologic Inc. acquired the company in 2006. Before joining R2 Technology, John was the president of the Ultrasound group at Siemens Healthcare, where he led the acquisition and integration of Acuson and subsequent growth of that company to $1 billion in revenue. He is based in Silicon Valley, California.
B Com, FCPA, FAICD
John is the principal of an Australian CPA firm that provides companies with corporate advisory services. John has extensive knowledge and practical experience in the application of Australian corporations law, ASX Listing Rules, international accounting standards and corporate governance principles.
Over the past 25 years John has managed the processes to raise capital, perform due diligence and seek ASX listing for a number of enterprises, including IPOs for a wide range of diverse offerings. These include oil and gas interests, food and retail, a fine wool processing plant, an innovative telephony product, a biotech company, an Internet advertising initiative, a dental device for snoring and sleep apnoea, an indoor skydiving company, the NZ developer of the Martin Jetpack, Skydive the Beach Group Limited (now renamed Experience Co Limited) and most recently, Oliver’s Real Food Limited.
John is currently a Non-Executive Director of ASX-listed Experience Co Limited, an adventure tourism business operating in Australia and New Zealand and a Non-Executive Director of Oliver's Real Food Limited, a healthy fast food chain operating on the highways in south-eastern Australia.
John is Chair of the Audit and Risk Committee and is based in Sydney, Australia.